AstraZeneca, Abbott Certriad deal a no go
After receiving a complete response letter from the FDA regarding a new drug application for Certriad, which is being investigated for the treatment of mixed dyslipidemia, AstraZeneca and Abbott Laboratories have decided to end development and their licensing agreement.
The FDA response letter, dated March 30, 2010, delayed regulatory approval, the London-based AstraZeneca said and the companies later determined that the drug was no longer “commercially attractive.”
Certriad contains two active ingredients, rosuvastatin calcium (Crestor) and fenofibric acid (Trilpix) and was also being investigated to treat a combination of two or more lipid abnormalities--high LDL cholesterol, high triglycerides and low HDL-cholesterol.
AstraZeneca said that the co-development and licensing agreement will cease Jan. 22. In addition, Abbott reported that there will be no financial impact to the company’s earnings per share in 2010 or 2011 due to the decision.
The FDA response letter, dated March 30, 2010, delayed regulatory approval, the London-based AstraZeneca said and the companies later determined that the drug was no longer “commercially attractive.”
Certriad contains two active ingredients, rosuvastatin calcium (Crestor) and fenofibric acid (Trilpix) and was also being investigated to treat a combination of two or more lipid abnormalities--high LDL cholesterol, high triglycerides and low HDL-cholesterol.
AstraZeneca said that the co-development and licensing agreement will cease Jan. 22. In addition, Abbott reported that there will be no financial impact to the company’s earnings per share in 2010 or 2011 due to the decision.